Non-Insulin Dependent Diabetes in Children and Adolescents: The Therapeutic Challenge

Abstract

Data are presented comparing non-insulin dependent diabetes mellitus (NIDDM) and insulin dependent diabetes mellitus (IDDM) in youth. Children and adolescents with NIDDM were predominantly Mexican-American, presented less frequently in ketoacidosis, had a greater frequency of family history of diabetes, had higher BMIs (27.4 vs 16.6 kg/m2), and had higher frequency of acanthosis nigricans (67% vs 1.2%). Logistical, social, and cultural challenges facing the physician treating children and adolescents with NIDDM are discussed, and treatment options for NIDDM in youth are briefly reviewed. Clin Pediatr. 1998;37:103-110

Get full access to this article

View all access options for this article.

References

Harris MI , Hadden Iwc , Knowler WC , et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. populations aged 20-74 years. Diabetes . 1987;36:523-534.

Banerji MA , Lebovitz HE Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38:784-792.

Arner P. , Pollare T. , Litthell H. Different aetiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia. 1991;34:483-487.

Hales CN The pathogensis of NIDDM. Diabetologia. 1994 ;37(suppl): 162-168.

Polonsky KS The β-cell in diabetes: from molecular genetics to clinical research . Diabetes. 1995;44:707-717.

Harris MI Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1994 ;17:1337-1340.

Gardner LI , Stern MP , Hazuda HP , et al. Prevalence of diabetes in Mexican Americans. Diabetes. 1983;33:86-92.

Raboudi SH , Mitchel BD , Stern MP , et al. Type II diabetes mellitus and polymorphism of insulin-receptor gene in Mexican Americans. Diabetes. 1989;38:975-980.

Bogardus C. Insulin resistance in the pathogenesis of NIDDM in Pima Indians. Diabetes Care. 1993;16:228-231.

10.

The DCCT Research Group. Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study . Diabetes Care. 1987;10:1-19.

11.

Neufeld N. , Raffel L. , Landon C. , et al. Childhood onset of type II diabetes mellitus in Hispanic Americans (abstract). Clin Res. 1993;40:70.

12.

Franz MJ , Horton ES , Bantle JP , et al. Nutritional principles for the management of diabetes and related complications. Diabetes Care. 1994;17:490-518.

13.

Jenkins Dja , Wolever Tms , Ocana AM , et al. Metabolic effects of reducing rate of glucose ingestion by single bolus versus continuous sipping . Diabetes. 1990;39:775-781.

14.

Jenkins Dja , Wolever Tms , Vuksan V. , et al. "Nibbling versus gorging": metabolic advantages of increased meal frequency. N Engl J Med. 1989 ;321:929-934.

15.

Lebovitz HE. Oral antidiabetic agents. In: Kahn CR , Weir GC , eds. Joslin's Diabetes Mellitus. Philadelphia: Waverly; 1994:508-529.

16.

Kolterman OG , Gray RX , Shapiro G. , et al. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 ;33:346-354.

17.

Gerich JE Oral hypoglycemic agents. N Engl J Med. 1989 ;321:1231-1245.

18.

Aguilar-Bryan L. , Nichols CG , Wechsler SW , et al. Cloning of the β-cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.

19.

Fajans SS Scope and heterogeneous nature of MODY. Diabetes Care . 1990;13:40-64.

20.

Groop LC , Pelkinen R. , Koskimies S. , et al. Secondary failure to treatment with oral antidiabetic agents in noninsulin dependent diabetes. Diabetes Care. 1986;9:129-133.

21.

Reaven GM Banting Lecture 1988: role of insulin resistance in human disease . Diabetes. 1988;37:1595-1607.

22.

Duckworth WC , Solomon SS , Kitabchi AE Effects of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol. 1972;35:585-591.

23.

Ferner RE , Neil Haw. Sulphonylureas and hypoglycaemia. Br Med J. 1988; 296:949-950.

24.

Lucin OJ The status of metformin in Canada. Can Med Assoc J. 1983;128:24-26.

25.

Vigneri R. , Goldfine ID Role of metformin in treatment of diabetes mellitus. Diabetes Care. 1987;10:118-122.

26.

Marchetti P. , Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. Clin Pharmacokinet. 1989;16: 100-128.

27.

Stumvoll M. , Nurjhan N. , Periello G. , et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus. N Engl J Med. 1995 ;333:550-554.

28.

Campbell IW , Menzies DG , Chalmers J. , et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab. 1994; 20:394-400.

29.

DeFronzo RA , Goodman AM , Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus . N Engl J Med. 1995;333:541-549.

30.

Bischoff H. Pharmacology of α-glucosidase inhibition . Eur J Clin Invest. 1994;3:3-10.

31.

Chiasson JL , Josse RG , Hunt JA , et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121:928-935.

32.

Coniff RF , Shapiro JA , Seaton TB , et al. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin dependent diabetes mellitus. Arn J Med. 1995;98: 443-451.

33.

Coniff RF , Shapiro JA , Robbins D. , et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study . Diabetes Care. 1995 ;18:817-824.

34.

Balfour JA , McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus . Drugs. 1993;46:1025-1054.

35.

The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.

36.

Reaven GM Role of insulin resistance in human disease. Diabetes . 1988;37: 1595-1607.

37.

Caro JF Insulin resistance in obese and nonobese men. J Clin Endocrinol Metab. 1991;73:691-695.

38.

Henry RR , Gumbiner B. , Ditzler T. , et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21-31.

39.

Abraira C. , Johnson N. , Colwell J. , et al. VA cooperative study on glycemic control and complications in type II diabetes (VACSCM) Diabetes Care. 1995 ;18:1113-1123.

40.

Turner RC , Phillips MA , Ward EA Ultralente based insulin regimens—clin— ical advantages and disadvantages . Acta Med Scand. 1983;671 (suppl):75-86.

41.

Henry RR , Gumbiner B. , Ditzler T. , et al. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21-31.

42.

Riddle MC Evening insulin strategy. Diabetes Care. 1990 ;13:676-686.

43.

Genuth S. Insulin use in NIDDM. Diabetes Care. 1990;13:1240-1260.

44.

Turner RC , Holman RR Insulin use in NIDDM; rationale based on pathophysiology of disease . Diabetes Care. 1990;13:1011-1020.

45.

Edelman SV , Henry RR Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes . Diabetes Rev. 1995;3:308-334.

46.

Suter SL , Nolan JJ , Wallace P. , et al. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 1992 ;15:192-203.

47.

Saltier AR , Olefsky JM Thiazolidinediones in the treatment of insulin resistance and type II diabetes . Diabetes. 1996;45:1661-1669.

48.

Iwamoto Y. , Kuzuya T. , Matsuda A. , et al. Effect of new oral antidiabetic agents CS045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care . 1991;14:1083-1086.

49.

Suter SL , Nolan JJ , Wallace P. , et al. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.

50.

Kumar S. , Boulton Ajm , Beck-Nielsen H. , et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996 ;39:701-709.